Devonian Health Group Inc. (CVE:GSD – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$5.10 and last traded at C$5.10, with a volume of 316 shares trading hands. The stock had previously closed at C$7.17.
Devonian Health Group Price Performance
The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The company’s 50 day simple moving average is C$10.50 and its 200 day simple moving average is C$11.34. The company has a market capitalization of C$14.18 million, a PE ratio of -2.27 and a beta of 0.44.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Further Reading
- Five stocks we like better than Devonian Health Group
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
